PBPK model predicts mitragynine exposure and potential drug interactions

Why it matters

A physiologically based pharmacokinetic model can support first-in-human dose selection and flag interaction questions before clinical testing of mitragynine.

The big picture

Researchers combined physicochemical and in vitro data with rat and dog pharmacokinetic studies, then simulated single and multiple doses in humans. The model also examined mitragynine as both an interacting drug and an interaction victim.

Key findings

• Potent CYP3A4 and CYP2D6 inhibitors had little effect on predicted mitragynine exposure; CYP3A4 inhibition reduced formation of 7-hydroxymitragynine; mitragynine increased midazolam exposure 2.2-2.7 fold; effects on CYP2D6 substrates were negligible.

What they say

The study reports that its model supports clinical translation of mitragynine and helps guide dose selection and interaction assessment.

Bottom line

**The model supports trial planning while identifying a potential CYP3A4-related interaction that requires human confirmation.**